Biodexa Pharmaceuticals plc · NASDAQ:BDRX
Biodexa Pharmaceuticals — Midatech Pharma — H1 2021 Earnings Presentation
15 slides from Biodexa Pharmaceuticals's earnings presentation, Sep 20, 2021
Slide 1: Interim Results, Six months ended 30 June 2021
Midatech Pharma plc Interim Results Six months ended 30 June 2021 20 September 2021 27/09/2021 1
Slide 2: Disclaimer
Disclaimer The following presentation, including a hard copy of these slides/the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation
Slide 3: Summary P&L
Summary P&L 1H 2021 1H 2020 1H 2021 vs 1H 2020 £m £m £m B/(W) % Revenue 0.40 0.17 0.23 139% R&D costs 2.01 3.99 1.98 50% Distribution, selling 0.02 0.01 (0.01) N/M Administrative costs 1.64 2.93 1.29 44% Impairment - 11.59 (11.59) N/M Operating loss (3.23) (18.35) (13.10) 82% Net loss (3.15) (17.42)
Slide 4: Summary Balance Sheet
Summary Balance Sheet 30 Jun 31 Dec 2021 2020 £m £m UK Placing raised £9.0m Fixed assets 1.25 0.54 (net) in July 2021 Receivables, taxation 2.82 1.73 Cash 4.20 7.55 All Spanish loans repaid Total assets 8.27 9.82 Liabilities – long term (0.68) (0.11) Cash runway into 1Q 23 Liabilities – short term (
Slide 5: Pipeline
Pipeline ID API Therapeutic Area Administration Formula- Preclinical Phase I Phase II Partner Status tion Q-Sphera: MTD211 brexpiprazole Schizophrenia / MDD LA injectable _ MTD219 tacrolimus Transplant rejection LA injectable _ MTX213 undisclosed undisclosed LA injectable Collaboration MTX214 undisc
Slide 6: MidaSolve – panobinostat infusion with CED
MTX110 MidaSolve – panobinostat infusion with CED Intratumoral brain cancer treatment 27/09/2021 6
Slide 7: MTX110 Glioblastoma Multiforme (GBM) prioritised
MTX110 Glioblastoma Multiforme (GBM) prioritised • GBM - much larger market potential 1400 Control TumVolume (mm3) 1200 MTX110 • 2-3 / 100,000 diagnoses pa1 1000 800 • Survival ranges from 13-30 mos depending on MGMT methylation2 600 400 • Rationale for MTX110 in GBM 200 0 0 5 10 15 20 25 30 35 40 •
Slide 8: MTX110 – Diffuse Intrinsic Pons Glioma (DIPG)
MTX110 – Diffuse Intrinsic Pons Glioma (DIPG) • Phase I programme (201 and 203 Trials): • Dose range selected for Phase II, excellent TI, encouraging overall survival • Phase II programme: • Phase II open-label • Newly-diagnosed patients (3-18 yrs) • Administration of MTX110 via pump and catheter Ga
Slide 9: Q-Sphera Programmes
Q-Sphera Programmes 27/09/2021 9
Slide 10: MTX214, MTX216 and MTX213: Partner collaborations
MTX214, MTX 216 and MTX213 : Partner collaborations • MTX214: • Proof of concept formulation (meets drug loading, injectability, dissolution criteria) • Shipped to partner in June for partner to undertake in vivo studies • In vivo data expected end Sep / early Oct • MTX216: • Proof of concept formul
Slide 11: MTD211: Q-brexpiprazole in vivo pharmacokinetics
MTD211: Q-brexpiprazole in vivo pharmacokinetics Plasma brexpiprazole concentrations in rabbits after a single SC Depot Injection (n=4) Q-BREXPIPRAZOLE BREXPIPRAZOLE SUSPENSION • Excellent Q-Sphera drug loading achieved (20%) enabling up to 90 days sustained delivery • Outperforms drug suspension ap
Slide 12: Modified release of biologics
Modified release of biologics • The challenge: • Large molecules (>150kDa) are delicate, easily ‘denatured’ in manufacturing • There are no approved, long acting formulations of mAbs • Midatech credentials: • Q-Sphera formulation / manufacturing process is relatively benign Exemplar structure of an
Slide 13: mAb assays show preserved functionality
mAb assays show preserved functionality Activity assay: Development and validation mAb encapsulated and released from Q-Sphera microspheres retains activity 1.5×10 7 120 150 Negative Control 100 1×10 7 Positive Control Signal Q Sphera Protein % Inhibition 80 100 % Inhibition 5×10 6 60 50 40 0 20 -12
Slide 14: Summary 1H scorecard
Summary 1H 21 scorecard • Costs under control, cash runway extended to 1Q 23 • Prioritising MTX110 for much larger GBM market • Delivered 2x Proof of Concept Q-Sphera formulations to partners • Initiated licensee search for Q-brexpiprazole • Opened up potential of Q-Sphera platform in proteins with
Slide 15: Thank You
Thank You 27/09/2021 15